Overview

A Study of Oxytocin PK After IV Administration in Healthy Subjects and Advanced Knee Arthritis Subjects

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
0
Participant gender:
All
Summary
The main purpose of this study is to sample the blood and calculate the pharmacokinetics (PK) of oxytocin. This is an unblinded, sequential study of subjects, all of whom will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain) with blood samples taken thereafter in order to create a formula to describe the concentrations of oxytocin in the blood over time (pharmacokinetics). In this study healthy volunteers and people with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Each study participant will have 2 IV catheters placed (one in each arm). After placement of the IV catheters and infusion of oxytocin will be given over a 10 minute period. Blood samples will be taken before the infusion begins and several times during and after the infusion. The blood will be drawn through the second IV catheter. The investigators will also do some tests to get a rough idea of how oxytocin changes perceptions on the skin and how this relates to the amount of oxytocin in the blood at the same time. Two kinds of perceptions will be studied. First, the investigators will study a painful perception by placing a probe on the skin and heating it to 113 degrees Fahrenheit for 5 minutes. Each study participant will score any pain that is experienced on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale. Secondly, the investigators will study the perception of vibration, like one feels with a tuning fork on the skin. For this the investigators will put a controlled vibration device on the arm and start the vibration at such a high frequency (1000 times per second) that it cannot be felt as vibrating. The investigators will slow the frequency until the study participant first feels vibration, then turn off the machine and record this threshold frequency where it is first felt.
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Oxytocin
Criteria
Inclusion Criteria:

- 1. Male or female > 18 and < 75 years of age, Body Mass Index (BMI) <40.

- 2. Generally in good health as determined by the Principal Investigator based on prior
medical history, American Society of Anesthesiologists physical status 1, 2, or 3.

- 3. For healthy volunteers, normal blood pressure (systolic 90-140 mmHg; diastolic
50-90 mmHg) resting heart rate 45-100 beats per minute) without medication. For knee
arthritis subjects, normal blood pressure or, for those with hypertension, pressure
controlled with anti-hypertensives and with a resting heart rate 45-100 beats per
minute.

- 4. Female subjects of child-bearing potential and those < 1 year post-menopausal, must
be practicing highly effective methods of birth control such as hormonal methods
(e.g., combined oral, implantable, injectable, or transdermal contraceptives), double
barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal
jellies or cream), or total abstinence from heterosexual intercourse for a minimum of
1 full cycle before study drug administration.

Exclusion Criteria:

- 1. Hypersensitivity, allergy, or significant reaction to any ingredient of PitocinĀ®

- 2. Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of
the Principal Investigator, would place the subject at increased risk (active
gynecologic disease in which increased tone would be detrimental e.g., uterine
fibroids with ongoing bleeding), compromise the subject's compliance with study
procedures, or compromise the quality of the data

- 3. Women who are pregnant (positive result for serum pregnancy test at screening
visit), women who are currently nursing or lactating, women that have been pregnant
within 2 years

- 4. Subjects with neuropathy, chronic pain, diabetes mellitus, or taking
benzodiazepines or pain medications on a daily basis.